ABOUT THE JOURNAL

The Journal of Sickle Cell Disease and Hemoglobinopathies (JSCDH), an official publication of the Foundation for Sickle Cell Disease Research (FSCDR) publishes peer-reviewed abstracts and articles of interest to clinicians, researchers, public health and health policy experts in the field of sickle cell disease and hemoglobinopathies. The Journal’s scope is multidisciplinary, representing all topics related to sickle cell disease and hemoglobinopathies. Original state-of-the-art reviews, clinical studies, experimental investigations, new therapeutics, case reports, editorials, articles on the business of sickle cell disease and hemoglobinopathies, feature articles and letters to the editor are published.

The Journal of Sickle Cell Disease and Hemoglobinopathies was established in 2013 as a forum for all physicians, scientists, allied healthcare, public health professionals, pharmaceutical and biotechnology researchers and developers, who are engaged or interested in sickle cell disease and hemoglobinopathies. The Journal seeks to support sickle cell disease and hemoglobinopathy specialists of all disciplines, improve patient care, and promote research and development by publishing peer-reviewed materials related to the field of sickle cell disease and hemoglobinopathies.

Online access to articles is restricted to subscribers and members of the Sickle Cell Research Society of America (SCRSA) for a period of 2 years after publication, after which time the materials are freely available to the public. In accordance with the National Institutes of Health (NIH) Public Access Policy, any article supported by a grant from the NIH is immediately available for access at PubMed Central. Funded open access to any article less than 2 years old is available upon request. Articles published under “Current Issue” or “Available Issues” are the version of record.

Author Instructions Abstracts and Manuscripts must address scientific hypothesis, significant clinical observations, have public health impact, or contain primary data.
Abstracts and Manuscripts submitted to the Journal of Sickle Cell Disease and Hemoglobinopathy cannot be submitted to other meetings and/or published once submitted JSCDH.

**Fees** There is a non-refundable handling fee for submitting an Abstract or Manuscript. There may be additional fees for extra photos, graphs, tables, supplemental documents, special handling or manipulation of graphics. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted.

**Abstract for the Annual Meeting** The abstract fee does not include registration for the annual meeting; therefore, all authors planning to attend the FSCDR annual meeting must register for the meeting.

**Revisions** No revisions can be made after the abstract submission deadline. The presentation at the annual meeting must reflect the submitted abstract with the exception of updates on results may be added.

**Language** Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission.